SCWD brings together leading voices in muscle biology and wasting disorders to explore mechanisms that continue to shape the field. In a featured 2025 session in Rome, Dr. Denis Guttridge and Prof. Andrea Bonetto discussed novel insights into muscle atrophy and hypertrophy mechanisms, highlighting how advances in preclinical and translational research are refining our understanding of sarcopenia, cachexia, and muscle wasting. These discussions reflect the core direction of SCWD,strengthening the link between basic science and clinical application, and improving how muscle disorders are studied across disease states. The themes remain highly relevant as the field continues to evolve, with ongoing emphasis on translational relevance, experimental design, and therapeutic development. SCWD 2026 in Washington, DC will continue to build on these scientific foundations, bringing together global experts working across cachexia, sarcopenia, adiposity, and muscle wasting to advance collaborative research and clinical translation. Register early for SCWD 2026: lnkd.in/gah9dmgS #SCWD #SCWD2026 #Cachexia #Sarcopenia #MuscleWasting #MuscleBiology #TranslationalMedicine #CancerCachexiaResearch #OncologyResearch #MetabolicHealth #WastingDisorders #MedicalCongress

At SCWD 2025, Prof. Christopher Perry highlighted the importance of integrating preclinical and clinical research environments to improve translational relevance in study design and how findings are understood. This ensures that muscle biology research is directly connected to muscle health and muscle wasting in clinical settings. He emphasized that this exchange of expertise not only refines experimental approaches but also supports more innovative directions in therapy development and diagnostic strategies for muscle disorders in cancer and beyond. SCWD continues to serve as a scientific platform where these interdisciplinary interactions shape how evidence is generated and translated into clinical impact. SCWD 2026 in Washington, DC will further this dialogue, bringing together researchers and clinicians working across cachexia, sarcopenia, adiposity, and muscle wasting to advance collaborative translational science: society-scwd.org/ #SCWD #SCWD2026 #WashingtonDC #Cachexia #Sarcopenia #MuscleWasting #Adiposity #IncretinTherapies #MetabolicHealth #WastingDisorders #CancerCachexiaResearch #OncologyResearch #EndocrinologyResearch #AbstractSubmission

Early bird registration for SCWD 2026 is now open. Advances in the understanding of cachexia, sarcopenia, adiposity, and muscle wasting continue to reshape how metabolic and chronic disease states are approached in both research and clinical practice. SCWD 2026 brings these evolving perspectives into a single scientific forum, fostering dialogue between translational research and clinical application. Early registration allows participation at the lowest available rate. Prices will increase after 5 September 2026. Washington, DC will host global experts working across these intersecting fields, where emerging evidence is not only presented but critically discussed to inform future directions in care and research. Register early for SCWD 2026 and secure the lowest rate: tinyurl.com/27j2btxt #SCWD #SCWD2026 #WashingtonDC #Cachexia #Sarcopenia #MuscleWasting #Adiposity #IncretinTherapies #MetabolicHealth #WastingDisorders #CancerCachexiaResearch #OncologyResearch #EndocrinologyResearch #AbstractSubmission

SCWD 2026 invites the global research community to present new evidence in Washington, DC. This is a platform dedicated to advancing understanding of cachexia, sarcopenia, adiposity, and muscle wasting, with growing interest in metabolic mechanisms and therapeutic approaches, including incretin-based therapies. We encourage submissions that contribute to translational and clinical insight, spanning pathophysiology, intervention strategies, and long-term outcomes in wasting disorders. High-quality abstracts will help shape scientific discussions that define future directions in this evolving field. Submit your abstract for SCWD 2026 and contribute to advancing research in wasting disorders: society-scwd.org/ #SCWD #SCWD2026 #WashingtonDC #Cachexia #Sarcopenia #MuscleWasting #Adiposity #IncretinTherapies #MetabolicHealth #WastingDisorders #CancerCachexiaResearch #OncologyResearch #EndocrinologyResearch #AbstractSubmission

At #ADA2026, SCWD's Accredited CE Breakfast Symposium, Optimizing Body Composition Changes in the Era of Incretin-Based Weight Loss Therapies: The New Frontier, was a tremendous success, bringing together healthcare professionals for a timely scientific discussion on body composition and weight loss. Strong attendance and active engagement throughout the session reflected the growing interest in understanding the effects of incretin-based therapies on muscle and fat, and how body composition can be optimized during weight loss. The symposium featured insights from an expert faculty covering body composition changes associated with incretin-based therapies, foundational concepts and terminology, modern assessment and imaging approaches, emerging strategies to preserve and build muscle, and the future of body composition optimization. Thank you to all attendees, speakers, and partners who contributed to an engaging and impactful educational session at ADA 2026. Stay tuned for key takeaways and session highlights: society-scwd.org/ #ADA2026 #BodyComposition #GLP1 #MuscleHealth #ObesityMedicine #DiabetesCare #SCWD #CME #ACCME

Happening now at #ADA2026. SCWD brings together leading experts to discuss a critical gap in incretin-based obesity care: understanding what weight loss truly means for body composition. From GLP-1 receptor agonists to dual GLP-1/GIP therapies, the focus goes beyond scale weight to fat and lean mass changes, standardized terminology, and how clinicians should interpret emerging evidence in practice. Join the discussion live in New Orleans: corereg.cmrus.com/ada2026 #ADA2026 #BodyComposition #GLP1 #MuscleHealth #ObesityMedicine #DiabetesCare #SCWD #CME #ACCME

Are you joining us at SCWD’s ACCME-accredited symposium in New Orleans? The incretin era is transforming obesity and metabolic care at speed, with GLP-1 receptor agonists and dual GLP-1/GIP therapies driving substantial weight loss. But a critical clinical question remains: what is happening to body composition during these changes, particularly skeletal muscle? At this symposium, leading experts will examine how clinicians should interpret fat versus lean mass changes, why standardized terminology is essential for consistent clinical understanding, and how different assessment approaches can shape interpretation in practice. The discussion will also explore emerging pharmacologic strategies aimed at preserving muscle during significant weight loss. Join us tomorrow for this focused, evidence-driven exchange at ADA 2026. Saturday, 6 June 2026 | 06:15 – 07:45 CDT St. Charles Ballroom | Hilton New Orleans Riverside, New Orleans Register Now: corereg.cmrus.com/ada2026 #ADA2026 #BodyComposition #GLP1 #MuscleHealth #ObesityMedicine #DiabetesCare #SCWD #CME #ACCME

Lean mass. Fat mass. Adiposity composition. Body composition. We use these terms as if they are interchangeable. They are not. In the incretin era, where patients are losing weight faster than ever, the terminology we use determines the conclusions we draw, and the clinical decisions that follow. Carla Prado, PhD, RD (University of Alberta) will define the framework at the SCWD symposium at #ADA2026. Foundational concepts. Standardized language. Practical clinical application. This is the vocabulary the field needs. June 6 | 6:15 AM CDT | New Orleans | ACCME accredited | 1.5 AMA PRA Category 1 Credits Register Now: corereg.cmrus.com/ada2026 #ADA2026 #BodyComposition #GLP1 #MuscleHealth #ObesityMedicine #DiabetesCare #SCWD #CME #ACCME

Five of the sharpest minds in body composition science. One room. One morning. Stefan D. Anker, MD, PhD | Charité–Universitätsmedizin Berlin A. Enrique Caballero, MD | Harvard Medical School Lars Johansson, PhD | CSO, Antaros Medical Carla Prado, PhD, RD | University of Alberta Donna H. Ryan, MD | Pennington Biomedical Research Center This is the faculty you want in the room when the conversation turns to what incretin-based therapies are actually doing to patients’ bodies. Saturday, June 6 | 6:15 AM CDT | St. Charles Ballroom, Hilton New Orleans Riverside, New Orleans ACCME accredited | 1.5 AMA PRA Category 1 Credits | 1.5 ANCC contact hours Register Now: corereg.cmrus.com/ada2026 #ADA2026 #BodyComposition #GLP1 #MuscleHealth #ObesityMedicine #DiabetesCare #SCWD #CME #ACCME

Only 2 Days Until ADA 2026! Will You Be Joining the Conversation? Are you ready to explore how incretin-based weight loss therapies are influencing what we see in clinical practice? Join leading experts at SCWD’s accredited CE breakfast symposium as they explore the latest evidence and emerging perspectives on body composition changes in the era of incretin-based weight loss therapies. Saturday, June 6 | 6:15 AM CDT | St. Charles Ballroom, Hilton New Orleans Riverside, New Orleans ACCME accredited | 1.5 AMA PRA Category 1 Credits Register today: corereg.cmrus.com/ada2026 #ADA2026 #BodyComposition #GLP1 #MuscleHealth #ObesityMedicine #DiabetesCare #SCWD #CME #ACCME

Are we paying enough attention to what happens beneath the scale during anti-obesity therapy? A recent article by Prof. Shahzeb Khan, "Fat, muscle, and anti-obesity medications in cardiovascular disease prevention," highlights an increasingly important discussion in obesity and cardiometabolic care: while anti-obesity medications are transforming treatment outcomes, understanding changes in body composition, not just body weight, may be critical to optimizing long-term patient health. The article explores emerging evidence around: - Fat mass reduction and cardiometabolic benefit - Skeletal muscle changes during weight loss therapy - The relationship between body composition and cardiovascular outcomes - Future opportunities to improve patient care through a more nuanced understanding of weight loss These are many of the same questions clinicians and researchers will be discussing at the upcoming SCWD educational symposium during hashtag#ADA2026: Optimizing Body Composition Changes in the Era of Incretin-Based Weight Loss Therapies: The New Frontier Join us - corereg.cmrus.com/ada2026 Hilton New Orleans Riverside Saturday, June 6, 2026 6:15–7:45 AM CDT #ADA2026 #ObesityMedicine #BodyComposition #GLP1 #CardiometabolicHealth #MuscleHealth #SCWD

I’m pleased to be speaking at SCWD’s accredited CE breakfast symposium at ADA 2026, where we’ll explore one of the most important questions in metabolic care today: How can we preserve and build muscle with emerging pharmacologic approaches? As incretin-based weight loss therapies continue to evolve, so does the need to better understand how we protect skeletal muscle while optimizing overall body composition outcomes. Join me at #ADA2026: corereg.cmrus.com/ada2026 Saturday, June 6 | 6:15 AM CDT | St. Charles Ballroom, Hilton New Orleans Riverside, New Orleans ACCME accredited | 1.5 AMA PRA Category 1 Credit #ADA2026 #BodyComposition #GLP1 #MuscleHealth #SCWD

Are you attending ADA 2026? If so, have you considered what body composition changes really mean in the era of incretin-based weight loss therapies? Join SCWD’s accredited CE breakfast symposium and hear leading experts discuss key questions shaping clinical practice today: • What happens to muscle and fat during incretin-based therapy? • How can emerging pharmacologic approaches help preserve and build muscle? June 6 | 6:15 AM CDT | New Orleans | ACCME accredited | 1.5 AMA PRA Category 1 Credits Register today: corereg.cmrus.com/ada2026 @AmDiabetesAssn | @ADA_DiabetesPro | @EASOobesity | @EASDnews | @DrCarlaPrado | @ShahzebKhanMD #ADA2026 #BodyComposition #GLP1 #MuscleHealth #ObesityMedicine #DiabetesCare #SCWD #CME #ACCME

Are we all speaking the same language when it comes to body composition? As incretin-based weight loss therapies continue to evolve, understanding how body composition terms are defined and applied in clinical practice and research is increasingly important. Join Prof. Carla Prado at SCWD’s accredited CE breakfast symposium at ADA 2026 as she explores the foundational concepts that help shape how we assess, discuss, and study body composition. Saturday, June 6 | 6:15 AM CDT | St. Charles Ballroom, Hilton New Orleans Riverside, New Orleans ACCME accredited | 1.5 AMA PRA Category 1 Credits | 1.5 ANCC contact hours Register today: corereg.cmrus.com/ada2026 @AmDiabetesAssn | @ADA_DiabetesPro | @EASOobesity | @EASDnews | @DrCarlaPrado | @ShahzebKhanMD #ADA2026 #BodyComposition #GLP1 #MuscleHealth #ObesityMedicine #SCWD

Are we confident that we are using the same language when discussing body composition in obesity and metabolic care? Hear from me at SCWD’s ACCME-accredited Breakfast Symposium at ADA 2026, where I will explore why standardized terminology is increasingly critical as incretin-based therapies reshape clinical practice. The language we use directly influences interpretation, communication, and decision-making in patient care. Saturday, June 6 | 6:15 AM CDT | St. Charles Ballroom, Hilton New Orleans Riverside, New Orleans ACCME accredited | 1.5 AMA PRA Category 1 Credits | 1.5 ANCC contact hours Register today: corereg.cmrus.com/ada2026 #ADA2026 #BodyComposition #GLP1 #MuscleHealth #ObesityMedicine #SCWD

The GLP-1 era is changing everything. But are we asking the right questions about what patients are actually losing? Body composition. Muscle. The science behind the number on the scale. SCWD is bringing this conversation to #ADA2026. Optimizing Body Composition Changes in the Era of Incretin-Based Weight Loss Therapies: The New Frontier Saturday, June 6 | 6:15 AM CDT | St. Charles Ballroom, Hilton New Orleans Riverside, New Orleans ACCME accredited | 1.5 AMA PRA Category 1 Credits | 1.5 ANCC contact hours Registration and breakfast from 5:30 AM Register today: corereg.cmrus.com/ada2026 #ADA2026 #BodyComposition #GLP1 #MuscleHealth #ObesityMedicine #DiabetesCare #SCWD #CME #ACCME

At the ASCO Annual Meeting 2026, an innovative clinical development programme evaluated mifomelatide (TCMCB07) for gastrointestinal cancer cachexia, integrating randomized Phase 2 trial data with real-world evidence. While oncology meetings introduce emerging findings, deeper scientific dialogue around cancer cachexia, muscle function, and therapeutic development continues within the dedicated muscle-wasting research community. The 19th International Conference on Sarcopenia, Cachexia & Wasting Disorders (#SCWD2026) brings together global experts specifically focused on advancing understanding, clinical management, and translational research in cancer cachexia, moving beyond oncology outcomes alone to address muscle health as a central component of patient care. Join the continued discussion at the 19th International Conference on Sarcopenia, Cachexia & Wasting Disorders #SCWD2026 this December in Washington, DC. Register now: cachexia.org #CancerCachexia #MuscleWasting #OncologyResearch #ClinicalTrials #GIcancer #SCWDConference2026 #ASCO2026 #CancerCachexiaResearch

Across obesity therapies, cancer cachexia, and sarcopenia research, muscle wasting is becoming a central focus in clinical and translational science. As these fields increasingly intersect, important questions are emerging around muscle preservation, metabolic response, and treatment-related changes in body composition. Abstract submissions for Society on Sarcopenia, Cachexia and Wasting Disorders 2026 are now open, inviting research across: - Obesity-related muscle loss - Cancer cachexia - Sarcopenia and muscle preservation strategies This is an opportunity to present new findings alongside leading experts working across evolving areas of muscle health research. Join the global scientific discussion at SCWD 2026: society-scwd.org/annual-conf… #SCWD2026 #MuscleWasting #CancerCachexia #CancerCachexiaResearch #Sarcopenia #ObesityResearch #MuscleHealth #SCWDConference2026